patronestaff-shutterstock-com
patronestaff / Shutterstock.com
17 December 2015PharmaAshley Roughton

Divide and destroy: an overview of poisonous divisionals

A patent application can in effect destroy itself. It works like this: a priority filing might claim a kinase which has an acceptable homology with a particular sequence listing—call that kinase-SL. The filing which is eventually made claims the kinase as originally claimed and a more general description of it, such as any kinase which has general binding characteristics for a class of proteins, of which kinase-SL is a member—call that the class of kinases.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Pharma
11 August 2026   A litigation campaign against generic drugmakers, including Sandoz, Hikma, and Amenal, raise the stakes in the fight over two of the world’s most lucrative weight loss and diabetes treatments.
Pharma
10 August 2026   Takanori Abe of Abe & Partners brings the perspective of a lawyer with first-hand experience in the German courtrooms to Pharmaceutical, Biological and Chemical Patents, a valuable resource on case law.
Pharma
6 August 2026   A Netherlands court ruling marks the latest win as Novo Nordisk ramps up efforts to protect semaglutide from unapproved products, copycats and an increasingly competitive market.